Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ARVN

Arvinas Inc

Dec 01 • 04:00PM ET

23.60

Dollar change +1.63
Percentage change 7.42	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.53	Insider Own	14.03%	Shs Outstand	53.20M	Perf Week	7.91%
Market Cap	1.30B	Forward P/E	-	EPS next Y	-7.24	Insider Trans	-0.02%	Shs Float	47.31M	Perf Month	47.68%
Income	-295.40M	PEG	-	EPS next Q	-1.29	Inst Own	86.20%	Short Float / Ratio	4.53% / 4.18	Perf Quarter	-15.26%
Sales	159.60M	P/S	8.14	EPS this Y	1.35%	Inst Trans	-1.42%	Short Interest	2.14M	Perf Half Y	1.59%
Book/sh	8.31	P/B	2.84	EPS next Y	-38.28%	ROA	-24.69%	Target Price	57.28	Perf Year	-42.50%
Cash/sh	18.24	P/C	1.29	EPS next 5Y	-	ROE	-54.77%	52W Range	13.57 - 42.52	Perf YTD	-31.01%
Dividend	-	P/FCF	-	EPS past 5Y	-42.94%	ROI	-64.34%	52W High	-44.50%	Beta	1.94
Dividend %	-	Quick Ratio	3.26	Sales past 5Y	106.15%	Gross Margin	95.55%	52W Low	73.91%	ATR	1.64
Employees	415	Current Ratio	3.26	Sales Q/Q	14.19%	Oper. Margin	-195.24%	RSI (14)	62.42	Volatility	9.46% 8.37%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	4.93%	Profit Margin	-185.09%	Rel Volume	1.60	Prev Close	21.97
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 07 BMO	Payout	-	Avg Volume	512.67K	Price	23.60
Recom	1.40	SMA20	19.54%	SMA50	27.40%	SMA200	-3.22%	Volume	820,635	Change	7.42%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Upgrade	Guggenheim	Neutral → Buy
Oct-23-23	Upgrade	Wedbush	Neutral → Outperform	$27 → $24
Jun-26-23	Resumed	Oppenheimer	Outperform	$95
Jan-12-23	Downgrade	Guggenheim	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$83 → $49
Sep-09-22	Initiated	Barclays	Overweight	$90
Jun-21-22	Initiated	Jefferies	Hold	$42
May-09-22	Downgrade	Wedbush	Outperform → Neutral
Apr-28-22	Initiated	Credit Suisse	Outperform	$104
Apr-06-22	Initiated	Morgan Stanley	Equal-Weight	$65
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$125
Feb-10-22	Initiated	Wells Fargo	Overweight	$98
Jan-19-22	Initiated	Goldman	Buy	$157
Dec-07-21	Initiated	Cowen	Outperform
Oct-14-21	Initiated	SVB Leerink	Outperform	$115
Sep-30-21	Initiated	Stifel	Buy	$115
Sep-09-21	Initiated	BofA Securities	Buy	$110
May-21-21	Initiated	UBS	Buy	$123
Apr-21-21	Initiated	Truist	Buy	$150
Mar-31-21	Initiated	BMO Capital Markets	Outperform	$101

Show Previous Ratings

Dec-01-23 09:55AM	Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect? (Zacks) +7.42%
Nov-28-23 05:05PM	Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-27-23 07:00AM	Arvinas Announces Oversubscribed $350 Million Private Placement (GlobeNewswire) +10.24%
Nov-15-23 09:55AM	Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should Know (Zacks)
Nov-13-23 09:55AM	Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +10.67%
08:02AM	Loading…
Nov-07-23 08:02AM	Arvinas Inc (ARVN) Reports Q3 2023 Financial Results and Provides Corporate Update (GuruFocus.com) +5.08%
07:00AM	Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-23 07:39AM	Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength? (Zacks) +6.90%
Oct-22-23 07:00AM	Potential of Arvinas' PROTAC AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC (GlobeNewswire)
Oct-18-23 07:00AM	Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day (GlobeNewswire) -6.56%
Oct-15-23 06:07PM	Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
06:05PM	Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Sep-01-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-23 10:54AM	Oppenheimer Says These 2 Beaten-Down Stocks Could Double Your Money Heres Why They Could Rebound (TipRanks)
07:06AM	Loading…
Aug-10-23 07:06AM	Wall Street Analysts Trim Price Targets for These 10 Stocks (Insider Monkey)
06:02AM	Growth Investors: Industry Analysts Just Upgraded Their Arvinas, Inc. (NASDAQ:ARVN) Revenue Forecasts By 13% (Simply Wall St.)
Aug-08-23 09:05AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-23 04:30PM	Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer (GlobeNewswire) +10.26%
Jul-06-23 09:00AM	Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination (GlobeNewswire) -5.94%
Jun-28-23 08:29PM	Goldman Sachs Says Attractive Valuations Make Small-Cap Stocks Appealing; Here Are 2 Strong Buy Names With Solid Upside Potential (TipRanks)
Jun-17-23 08:57AM	Loss-making Arvinas (NASDAQ:ARVN) has seen earnings and shareholder returns follow the same downward trajectory over past -24% (Simply Wall St.)
Jun-15-23 04:30PM	Arvinas Announces Changes to its Board of Directors (GlobeNewswire)
Jun-13-23 04:51AM	Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last? (Zacks) +9.21%
Jun-08-23 01:05PM	Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations (Benzinga)
07:00AM	Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations (GlobeNewswire)
Jun-05-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-23 07:00AM	Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress (GlobeNewswire)
May-07-23 08:04AM	New Forecasts: Here's What Analysts Think The Future Holds For Arvinas, Inc. (NASDAQ:ARVN) (Simply Wall St.)
08:35AM	Loading…
May-05-23 08:35AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +7.61%
07:00AM	Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-23 07:00AM	Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
May-02-23 01:00PM	Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial (PR Newswire) -7.69%
Apr-21-23 04:00PM	Arvinas to Present at Stifel Targeted Oncology Day (GlobeNewswire) +5.51%
Apr-17-23 08:01AM	Arvinas, Inc. (NASDAQ:ARVN) Investors Are Less Pessimistic Than Expected (Simply Wall St.)
Apr-14-23 03:32AM	Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Apr-03-23 07:00AM	Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership (GlobeNewswire)
Feb-27-23 04:00PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 05:10AM	A Look At The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN) (Simply Wall St.)
05:10AM	Arvinas Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Feb-23-23 08:45AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-06-23 04:30PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-11-23 08:35AM	Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock? (Zacks)
Jan-04-23 07:00AM	Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.22%
Jan-03-23 07:11AM	Investors in Arvinas (NASDAQ:ARVN) from a year ago are still down 57%, even after 5.4% gain this past week (Simply Wall St.)
Dec-16-22 09:00AM	Arvinas Announces Changes to its Board of Directors (GlobeNewswire)
Nov-25-22 04:04AM	Analysts Say These 2 Strong Buy Stocks Are Their Top Picks for 2023 (TipRanks)
Nov-22-22 11:20AM	Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting (Benzinga) -5.52%
07:12AM	Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) (GlobeNewswire)
Nov-08-22 08:15AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-22 04:00PM	Arvinas to Present at Upcoming Conferences (GlobeNewswire)
08:32AM	Why Arvinas (ARVN) Might Surprise This Earnings Season (Zacks)
Oct-27-22 11:04AM	Strength Seen in Arvinas, Inc. (ARVN): Can Its 12% Jump Turn into More Strength? (Zacks)
07:00AM	Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award (GlobeNewswire)
Oct-03-22 07:00AM	Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Sep-30-22 09:00AM	Arvinas Gives Back to Local Greater New Haven Community (GlobeNewswire)
Sep-26-22 07:00AM	Arvinas to Present at Bank of America Securities Precision Oncology Conference (GlobeNewswire)
Sep-13-22 10:17AM	hC Bioscience Appoints Brad Margus to its Board of Directors (GlobeNewswire)
Aug-31-22 07:00AM	Arvinas to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-22 04:01PM	Arvinas Announces Changes to its Board of Directors (GlobeNewswire)
Aug-15-22 09:13AM	15 Small Company Stocks You Should Own Now for the Next Decade (Insider Monkey)
07:00AM	Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations (GlobeNewswire)
Aug-04-22 08:35AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-22 07:00AM	Arvinas Appoints John Northcott as Chief Commercial Officer (GlobeNewswire) -5.14%
Jul-27-22 07:12AM	Those who invested in Arvinas (NASDAQ:ARVN) three years ago are up 94% (Simply Wall St.)
Jul-06-22 04:10PM	Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names (Investor's Business Daily)
Jun-27-22 08:52AM	Arvinas, Inc. (ARVN) Stock Jumps 8%: Will It Continue to Soar? (Zacks)
Jun-02-22 04:00PM	Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
Jun-01-22 08:00AM	Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations (GlobeNewswire)
May-10-22 08:26AM	Investing in These 3 Healthcare Stocks Could Double Your Money, Says Credit Suisse (TipRanks) +9.78%
May-09-22 10:00AM	GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration (PR Newswire) -15.63%
May-05-22 08:15AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -9.94%
07:00AM	Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 07:00AM	Arvinas to Present at Bank of America Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-26-22 03:01PM	Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.85%
Mar-04-22 07:00AM	Arvinas to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-02-22 11:22AM	Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag (Zacks)
Feb-28-22 08:25AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-22 10:14AM	Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
Feb-24-22 10:15AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-17-22 08:00AM	Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire)
04:40AM	Despite shrinking by US$144m in the past week, Arvinas (NASDAQ:ARVN) shareholders are still up 227% over 3 years (Simply Wall St.)
Feb-15-22 12:50PM	Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients (Benzinga)
Feb-14-22 06:04PM	Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting (GlobeNewswire)
Feb-03-22 04:30PM	Arvinas to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-31-22 09:04AM	Goldman Sachs Bets on These 3 Strong Buy Stocks (TipRanks) +8.48%
Jan-06-22 05:38PM	Canton Hathaway, LLC Buys Amplify Lithium & Battery Technology ETF, Raytheon Technologies ... (GuruFocus.com)
Dec-13-21 04:38PM	Deutsche Dws Variable Series Ii Buys Dynatrace Inc, CarGurus Inc, National Vision Holdings Inc, ... (GuruFocus.com)
Dec-12-21 11:00AM	Should I Avoid Arvinas, Inc. (ARVN)? (Insider Monkey)
Dec-10-21 10:40AM	Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients (Benzinga) -6.83%
08:10AM	Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer (GlobeNewswire)
Nov-19-21 09:55AM	Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium (GlobeNewswire)
04:24AM	What Kind Of Shareholders Hold The Majority In Arvinas, Inc.'s (NASDAQ:ARVN) Shares? (Simply Wall St.)
Nov-18-21 10:28AM	Notable Arvinas Insider Trades $2.0M In Company Stock (Benzinga)

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Peck Ronald	Chief Medical Officer	Aug 11	Sale	24.39	1,324	32,289	29,965	Aug 14 05:27 PM
Houston John G	President and CEO	Mar 01	Sale	29.53	5,878	173,577	917,427	Mar 03 09:50 PM
Cassidy Sean A	Chief Financial Officer	Mar 01	Sale	29.53	1,745	51,530	183,618	Mar 03 09:49 PM
Taylor Ian	Chief Scientific Officer	Mar 01	Sale	29.53	1,051	31,036	101,721	Mar 03 09:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARVN

Arvinas Inc

Upgrade your FINVIZ experience